• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOCOMPATIBLES UK LTD THERASPHERE; YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOCOMPATIBLES UK LTD THERASPHERE; YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW Back to Search Results
Model Number UNKNOWN
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Abdominal Pain (1685); Fever (1858)
Event Date 10/09/2017
Event Type  Injury  
Manufacturer Narrative
The events were reported through a retrospective clinical trial.The events are considered serious and possibly related to therasphere (reporting investigator), related to patient condition (btg medical assessment).Btg medical assessment: 60 year-old male was treated with therasphere® in (b)(6) 2017 and again in (b)(6) 2017 due to residual/recurrent disease.Had been experiencing abdominal pain for several days and per phone call with physician on (b)(6) 2017 was instructed to take prevacid or prilosec.Ultimately went to er and was admitted to hospital.Per edc: "telephone encounter on (b)(6) 2017: spoke with patients wife.Patient was at (b)(6) for one night for abdominal pain and fever and home now feeling better.He did have bilat ultrasound of groins report reads bilateral common femoral arteries widely patent.There is no sonographic evidence of pseudoaneurysm or hematoma in either groin." hospital admission (b)(6) 2017.No ongoing complaints noted at (b)(6) 2017 follow up visit.Limited information available other than details in the follow up office note as the patient was treated for this event at an outside facility.Btg is unable to assess if the medical intervention was taken to prevent a permanent damage to a body structure or function based on the information provided.Abdominal pain: serious; severity 3; related (resolved with adapted treatment) fever: serious; severity 3; related.Abdominal pain and fever are anticipated adverse events listed in the ifu/risk management documentation.The events were not reported to btg in 2017.No device malfunction was reported and no corrective and preventive action (capa) plan has been identified.The lot number associated with the therasphere administration was not reported, therefore no investigation could be performed.If additional information becomes available, a follow up report will be submitted.No other information is available that could confirm/deny the alleged event.At this time this report is considered final.
 
Event Description
Auto-notifications received from datatrak 29-jul-2019 as follows: subject: (b)(6) is a 60 year-old male, white, patient enrolled on the retrospective (b)(6) study.Diagnosed with hcc: (b)(6) 2017.Hcc etiology: hepatitis c, solitary lesion at location viii, bclc classification: c (ecog 1).Total liver volume 1123 (ml).Future remnant liver volume 466 (ml).1st treated with therasphere: (b)(6) 2017.1 vial administered - total administered activity: 0.974 gbq.Total volume of perfused liver: 326 (cm3).Volume of treated lobe: 657 (cm3).2nd therasphere treatment: (b)(6) 2017.Lung shunt fraction 2.9%.1 vial administered - total administered activity: 0.771.Whole liver volume: 1358 (cm3).Total volume of perfused liver: 289 (cm3).Volume of treated lobe: 776 (cm3).On 09-oct-2017 patient experienced fever and abdominal pain which lead to overnight hospitalization (b)(6) 2017.They had a bilateral ultrasound of groins and the report reads "bilateral common femoral arteries widely patent.There is no sonographic evidence of pseudoaneurysm or hematoma in either groin".Patient was discharged (b)(6) 2017.Outcome: resolved (b)(6) 2017.Fever: sae.Severity grade 3.Unrelated to procedure.Possibly related to therasphere.Abdominal pain: sae.Severity grade 3.Unrelated to procedure.Possibly related to therasphere.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
THERASPHERE
Type of Device
YTTRIUM-90 GLASS MICROSPHERES, PRODUCT CODE: NAW
Manufacturer (Section D)
BIOCOMPATIBLES UK LTD
chapman house farnham bus park
weydon lane
farnham, GU9 8 QL
UK  GU9 8QL
Manufacturer (Section G)
BIOCOMPATIBLES UK
chapman house
weydon lane
farnham, GU9 8 QL
UK   GU9 8QL
Manufacturer Contact
sandra bausback-aballo
300 four falls corporate cente
300 conshohocken state road
west conshohocken,, PA 19428-2998
6103311537
MDR Report Key8868289
MDR Text Key154460934
Report Number3002124543-2019-00055
Device Sequence Number1
Product Code NAW
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
H980006
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type health professional,study
Reporter Occupation Physician
Type of Report Initial
Report Date 07/29/2019
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received08/07/2019
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Model NumberUNKNOWN
Device Catalogue NumberN/A
Device Lot NumberUNKNOWN
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received07/29/2019
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Required Intervention;
Patient Age60 YR
-
-